IKT – inhibikase therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Inhibikase Therapeutics (IKT) was upgraded by LADENBURG THALM/SH SH to "strong-buy".
Inhibikase Therapeutics (IKT) is now covered by LADENBURG THALM/SH SH. They set a "buy" rating and a $4.00 price target on the stock.
Inhibikase Therapeutics (IKT) was upgraded by Lifesci Capital to "strong-buy".
Inhibikase Therapeutics (NASDAQ:IKT) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Inhibikase Therapeutics (NYSE:IKT) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $6.00 price target on the stock.
Form 4 Inhibikase Therapeutics, For: Feb 21 Filed by: Cabell Christopher
Form 4 Inhibikase Therapeutics, For: Feb 21 Filed by: Aurentz Vincent
Form 4 Inhibikase Therapeutics, For: Feb 21 Filed by: Munshi Amit
Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: ADAR1 Capital Management, LLC
Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: Fairmount Funds Management LLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.